|
|
| Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
| Bank Loan Ratings | 7.50 | ACUITE B- | Reaffirmed & Withdrawn | Issuer not co-operating* | - |
| Total Outstanding Quantum (Rs. Cr) | 0.00 | - | - |
| Total Withdrawn Quantum (Rs. Cr) | 7.50 | - | - |
| Rating Rationale |
|
Acuité has reaffirmed and withdrawn the long-term rating of ‘ACUITE B-’ (read as ACUITE B Minus) on the Rs.7.50 Crore bank facilities of Tara Biosciences Private Limited (TBPL). The rating continues to be flagged as “Issuer Not Cooperating” and is based on the best available information.
The rating has been withdrawn on Acuite's policy of withdrawal of ratings. The rating has been withdrawn on account of the request received from the company, and the NOC received from the banker. |
| About the Company |
|
Delhi-based TBPL was incorporated in 2007 and began operations in 2016. The company is currently headed by Dr Hitendra Singh Yadav, Dr Monika Singh and Mrs. Leela Shethi. TBPL is engaged in the manufacturing of IV infusions/ Lifesaving drugs in 3 variants- LPI (Large Volume Infusions), SPI (Small Volume Infusions) and water infusions (saline water). Further, TBPL has an in house research and laboratory spread across 10,000 sq.ft with 25 people working in this department.
|
| Non-cooperation by the issuer/borrower: |
|
Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date. Acuité believes that information risk is a critical component in such ratings, and noncooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating is, therefore, being flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies.
|
| Limitation regarding information availability: |
|
The rating is based on information available from sources other than the issuer/borrower (in the absence of information provided by the issuer/borrower). Acuité endeavoured to gather information about the entity/industry from the public domain. Therefore, Acuité cautions lenders and investors regarding the use of such information, on which the indicative credit ratingis based. |
| About the Rated Entity - Key Financials |
|
The rated entity has not shared the latest financial statements despite repeated requests. |
| Rating Sensitivity |
|
"No information provided by the issuer / available for Acuite to comment upon." |
| Material Covenants |
|
Not Applicable |
| Liquidity Position |
|
"No information provided by the issuer / available for Acuite to comment upon." |
| Outlook |
|
Not Applicable |
| Other Factors affecting Rating |
| None |
| Status of non-cooperation with previous CRA |
|
None |
| Any other information |
| Acuité is yet to receive the latest No Default Statement (NDS) from the rated entity, despite repeated requests and follow-ups. |
| Applicable Criteria |
|
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
| Note on Complexity Levels of the Rated Instrument |
|
In order to inform the investors about complexity of instruments, Acuité has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite’s categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria “Complexity Level Of Financial Instruments” on www.acuite.in.
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
|
|
Contacts |
| Analytical | Rating Desk |
| About Acuité Ratings & Research |
